CC
C4 Therapeutics, Inc.
CCCC · NASDAQ
$3.76 +1.08% (+$0.04)
1M +3.30%
Market Cap $413.5M
P/E Ratio -
Div. Yield -
ROE 45.45%
Piotroski F-Score Weak
3/9Valuation
48 /100
Fair P/B 1.67x
P/S 11.80x
P/FFO N/A
Growth
36 /100
Stable Book val. growth 3.91%
Rev. growth 4.95%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 318.97%
Gross margin 94.86%
FCF margin 243.71%
Quality
1 /100
Poor ROA 28.22%
ROIC 35.21%
Asset turnover 0.10x
Debt
100 /100
Low Current ratio 5.45x
Debt/Equity 0.23x
Debt/Assets N/A
Stability
25 /100
Unstable EPS volatility 22.62%
Beta 2.95x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o CCCC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Andrew J. Hirsch
Employees
104
Headquarters
Watertown
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report